Kamada (KMDA) Earnings Date & Reports

Key Takeaways

• Kamada reported third-quarter 2026 revenue of $52.03 million, up 11% from $47.01 million a year earlier.
• Nine-month revenue reached a record $152.2 million, an increase of approximately 12% year over year.
• Diluted earnings per share (EPS) of $0.14 beat the consensus estimate of $0.13, while revenue came in slightly below the $52.76 million estimate.
• Third-quarter net income climbed 51% to $8.0 million, and adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) rose 30% to $15.2 million.
• Management raised full-year 2026 guidance and projected continued double-digit revenue and profit growth in 2027.
• For additional detail on KMDA's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated pages on Tickeron.
• Looking for data-driven trading ideas? Explore Trending AI Robots to see how AI-driven strategies are applied across the market.

Earnings Context and Why It Matters

Kamada is a global biopharmaceutical company focused on specialty plasma-derived therapies and a portfolio of products for rare and serious conditions. Its third-quarter report matters because it offers investors a read on demand for lead products such as KEDRAB, an anti-rabies immunoglobulin, alongside VARIZIG and HEPAGAM B. The company has delivered a string of double-digit revenue gains as U.S. utilization expands, and this quarter tests whether that momentum can continue while margins improve. The results also carry weight for the company's broader strategy of expanding plasma collection and building its biosimilar distribution business, both of which are expected to shape long-term profitability.

Reported Results

Kamada reported third-quarter 2026 revenue of $52.03 million, up 11% from $47.01 million a year ago, while nine-month revenue reached a record $152.2 million, a roughly 12% increase. Diluted EPS came in at $0.14, up from $0.09 a year earlier and slightly ahead of the $0.13 consensus estimate; revenue, however, was modestly below the $52.76 million analysts had projected.

Net income for the quarter was $8.0 million, up 51% year over year, with adjusted EBITDA of $15.2 million, up 30% and representing a 29% margin. Gross profit was $23.3 million, with a gross margin of 45%. For the nine-month period, net income totaled $21.4 million, or $0.37 per diluted share, up 29%, while adjusted EBITDA rose 20% to $40.9 million. Operating cash flow for the first nine months reached $37.6 million, up from $17.9 million a year earlier, and cash and short-term investments stood at $75.3 million at quarter-end.

Management raised full-year 2026 guidance to revenue of $205 million to $208 million and adjusted EBITDA of $52 million to $54 million, from a prior range of $200 million to $205 million and $50 million to $53 million. The company also declared a $0.14 per-share dividend, bringing total 2026 dividends to roughly $32.3 million.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is built to surface trade ideas, trending stocks, and breakout candidates more efficiently than manual screening, helping investors narrow their focus in a crowded market. For those tracking earnings-driven moves like Kamada's, it can be a practical starting point for identifying opportunities.

Market Reaction and Investor Sentiment

The third-quarter print was broadly positive but mixed relative to expectations. A beat on EPS alongside record nine-month sales and raised guidance supported the growth narrative, while the slight revenue miss against consensus and a modestly lower nine-month gross margin of 43% (versus 44% a year earlier) gave investors points to scrutinize. Sentiment heading into the report had been shaped by expanding U.S. demand for KEDRAB, which management says holds at least 50% market share, and by early-stage progress in plasma collection and biosimilars. The dividend declaration and the projection of double-digit growth in 2027 reinforced confidence in the company's cash generation and commercial momentum.

Forward Outlook and Key Factors to Monitor

Kamada's raised 2026 guidance signals management's confidence that current demand trends will continue. Investors will be watching whether KEDRAB utilization in the U.S. keeps rising above distributor Kedrion's minimum commitment, particularly given the company's stated inventory and manufacturing capacity to support further growth.

Plasma collection represents another area of focus. Normal source plasma sales are expected to begin in the fourth quarter of 2026 under a three-year agreement, but the financial benefit of vertical integration is still developing. Because collected plasma must pass through validation before contributing to profitability, the timing and scale of that contribution will be a key factor in the quarters ahead.

The distribution segment, which grew 35% to $24.1 million in the first nine months, is also worth monitoring. New biosimilar launches in Israel and expansion into the Middle East and North Africa (MENA) region provide additional growth avenues. Management has guided for biosimilar revenue of roughly $10 million in 2028 and $20 million to $25 million by 2030.

Finally, mergers and acquisitions (M&A) remain central to the company's four-pillar strategy. Management has indicated that opportunities are in hand, and any completed transaction could accelerate growth beyond the current organic trajectory. Cost discipline and gross-margin trends will also be watched closely as operating expenses rise to support expanded commercial operations.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations